Literature DB >> 28626055

Ischemic Stroke: What Does the Histological Composition Tell Us About the Origin of the Thrombus?

Peter B Sporns1, Uta Hanning2, Wolfram Schwindt2, Aglaé Velasco2, Jens Minnerup2, Tarek Zoubi2, Walter Heindel2, Astrid Jeibmann2, Thomas Ulrich Niederstadt2.   

Abstract

BACKGROUND AND
PURPOSE: The introduction of stent retrievers allows for a complete extraction and histological analysis of human thrombi. Ischemic stroke is a major health issue, and differentiation of underlying causes is highly relevant to prevent recurrent stroke. Therefore, histopathologic analysis of the embolic clots after removal may provide valuable information about underlying pathologies. This study analyzes histological clot composition and aims to identify specific patterns that might help to distinguish causes of ischemic stroke.
METHODS: Patients with occlusion of the carotid-T or middle cerebral artery who underwent thrombectomy at our university medical center between December 2013 and February 2016 were included. Samples were histologically analyzed (hematoxylin and eosin, Elastica van Gieson, and Prussian blue), additionally immunohistochemistry for CD3, CD20, and CD68/KiM1P was performed. These data, along with additional clinical and interventional parameters, were compared for different stroke subtypes, as defined by the TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification.
RESULTS: One hundred eighty-seven patients were included, of these, in 77 patients, cardioembolic; in 46 patients, noncardioembolic; and in 64 patients, cryptogenic pathogenesis was determined. Cardioembolic thrombi had higher proportions of fibrin/platelets (P=0.027), less erythrocytes (P=0.005), and more leucocytes (P=0.026) than noncardioembolic thrombi. We observed a strong overlap of cryptogenic strokes and cardioembolic strokes concerning thrombus histology. The immunohistochemical parameters CD3, CD20, and CD68/KiM1P showed no statistically noticeable differences between stroke subtypes.
CONCLUSIONS: Histological thrombus features vary significantly according to the underlying cause and may help to differentiate between cardioembolic and noncardioembolic stroke. In addition, our study supports the hypothesis that most cryptogenic strokes have a cardioembolic cause.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  blood platelets; embolism; fibrin; thrombectomy; thrombosis

Mesh:

Year:  2017        PMID: 28626055     DOI: 10.1161/STROKEAHA.117.016590

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  50 in total

1.  Platelet-Rich Emboli in Cerebral Large Vessel Occlusion Are Associated With a Large Artery Atherosclerosis Source.

Authors:  Seán Fitzgerald; Daying Dai; Shunli Wang; Andrew Douglas; Ramanathan Kadirvel; Kennith F Layton; Ike C Thacker; Matthew J Gounis; Ju-Yu Chueh; Ajit S Puri; Mohammed Almekhlafi; Andrew M Demchuk; Ricardo A Hanel; Eric Sauvageau; Amin Aghaebrahim; Albert J Yoo; Peter Kvamme; Vitor M Pereira; Yasha Kayan; Josser E Delgado Almandoz; Raul G Nogueira; Alejandro A Rabinstein; David F Kallmes; Karen M Doyle; Waleed Brinjikji
Journal:  Stroke       Date:  2019-05-29       Impact factor: 7.914

Review 2.  Correlation of imaging and histopathology of thrombi in acute ischemic stroke with etiology and outcome: a systematic review.

Authors:  Waleed Brinjikji; Sharon Duffy; Anthony Burrows; Werner Hacke; David Liebeskind; Charles B L M Majoie; Diederik W J Dippel; Adnan H Siddiqui; Pooja Khatri; Blaise Baxter; Raul Nogeuira; Matt Gounis; Tudor Jovin; David F Kallmes
Journal:  J Neurointerv Surg       Date:  2016-05-10       Impact factor: 5.836

3.  The role of diabetes mellitus on the thrombus composition in patients with acute ischemic stroke.

Authors:  Gengfan Ye; Qun Gao; Peng Qi; Junjie Wang; Shen Hu; Kunpeng Chen; Tianhua Tan; Jun Lu; Daming Wang
Journal:  Interv Neuroradiol       Date:  2020-01-10       Impact factor: 1.610

4.  Therapeutic effect of pre-operative tirofiban on patients with acute ischemic stroke with mechanical thrombectomy within 6-24 hours.

Authors:  Ying Luo; Yang Yang; Yang Xie; Zhengzhou Yuan; Xiaogang Li; Jinglun Li
Journal:  Interv Neuroradiol       Date:  2019-05-21       Impact factor: 1.610

5.  Susceptibility Vessel Sign and Cardioembolic Etiology in the THRACE Trial.

Authors:  Romain Bourcier; Imad Derraz; Béatrice Delasalle; Marine Beaumont; Sebastien Soize; Laurence Legrand; Hubert Desal; Serge Bracard; Olivier Naggara; Catherine Oppenheim
Journal:  Clin Neuroradiol       Date:  2018-06-12       Impact factor: 3.649

Review 6.  Acid-Base and Electrolyte Changes Drive Early Pathology in Ischemic Stroke.

Authors:  Sarah R Martha; Justin F Fraser; Keith R Pennypacker
Journal:  Neuromolecular Med       Date:  2019-07-06       Impact factor: 3.843

Review 7.  Clot Pathophysiology: Why Is It Clinically Important?

Authors:  Patrick A Brouwer; Waleed Brinjikji; Simon F De Meyer
Journal:  Neuroimaging Clin N Am       Date:  2018-09-15       Impact factor: 2.264

8.  Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis.

Authors:  Lucas Di Meglio; Jean-Philippe Desilles; Véronique Ollivier; Mialitiana Solo Nomenjanahary; Sara Di Meglio; Catherine Deschildre; Stéphane Loyau; Jean-Marc Olivot; Raphaël Blanc; Michel Piotin; Marie-Christine Bouton; Jean-Baptiste Michel; Martine Jandrot-Perrus; Benoît Ho-Tin-Noé; Mikael Mazighi
Journal:  Neurology       Date:  2019-09-20       Impact factor: 9.910

9.  Is Histologic Thrombus Composition in Acute Stroke Linked to Stroke Etiology or to Interventional Parameters?

Authors:  J Goebel; B-J Gaida; I Wanke; C Kleinschnitz; M Koehrmann; M Forsting; C Moenninghoff; A Radbruch; A Junker
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-19       Impact factor: 3.825

10.  A murine photothrombotic stroke model with an increased fibrin content and improved responses to tPA-lytic treatment.

Authors:  Yu-Yo Sun; Yi-Min Kuo; Hong-Ru Chen; Jonah C Short-Miller; Marchelle R Smucker; Chia-Yi Kuan
Journal:  Blood Adv       Date:  2020-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.